Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADA | P00813 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30527997 | 0.97 | LMNA (0.50) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL15228305 | 0.91 | KMO (0.50) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL22544553 | 0.89 | LMNA (0.48) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL3032664 | 0.85 | LMNA (0.40) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL1660871 | 0.85 | LCK (0.41) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL31196442 | 0.84 | SIRT6 (0.50) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL8148229 | 0.84 | SIRT6 (0.41) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL2774815 | 0.84 | SIRT6 (0.50) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL24714018 | 0.79 | CDK8 (0.43) | LMNAADORA3TSHRMC4RADRA1A | |
| SCHEMBL12295188 | 0.79 | POLB (0.40) | LMNAADORA3TSHRMC4RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2013-11-28 | — | — | US | claimed |
| EP-2542086-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myrexis, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | US | claimed |
| WO-2011109441-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| EP-0418797-B1 | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds | HOECHST AG (DE) | 1994-08-24 | — | — | EP | claimed |
| US-5130317-A | Immunosuppressants and fibrosuppressants for metabolism of collagen | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-14 | — | — | US | claimed |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4251615-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| CN-116478378-A | Iridium-based catalyst of aromatic heterocyclic porous organic polymer, preparation method and application | 大连理工大学 | 2023-07-25 | — | — | CN | disclosed |
| WO-2022112188-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
| US-20050004111-A1 | Degenerative joints disease; osteoarthritis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| US-20050004111-A1 | Degenerative joints disease; osteoarthritis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-06 | — | — | US | disclosed |
| WO-2004041788-A1 | NOVEL PYRIMIDINE-4,6-DICARBOXAMIDES FOR THE SELECTIVE INHIBITION OF COLLAGENASES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-05-21 | — | — | WO | disclosed |
| EP-0418797-B1 | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds | HOECHST AG (DE) | 1994-08-24 | — | — | EP | disclosed |
| US-5130317-A | Immunosuppressants and fibrosuppressants for metabolism of collagen | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-07-14 | — | — | US | disclosed |
| EP-0418797-A2 | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-27 | — | — | EP | disclosed |
| EP-0418797-A2 | Pyrimidin-4,6-dicarboxilic acid diamides, process for their preparation also medicine based on those compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160367541-A1 | THERAPEUTIC AND DIAGNOSTIC METHODS | NAMPT, NAPRT, NNT | LMNA 1146/4885ADORA3 766/4885TSHR 3086/4885 |
| US-20150353538-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | LMNA 4409/4885ADORA3 958/4885TSHR 1688/4885 |
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | PC, CPS1, GLS2 | LMNA 4183/4885ADORA3 691/4885TSHR 3550/4885 |
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | LMNA 1803/4885ADORA3 878/4885TSHR 1218/4885 |
| US-20120329786-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | LMNA 4409/4885ADORA3 958/4885TSHR 1688/4885 |
| US-20050004111-A1 | Degenerative joints disease; osteoarthritis | MMP13, ADAMTS13, DPYD | LMNA 2372/4885ADORA3 501/4885TSHR 4139/4885 |
| US-20130317027-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD47, CD4 | LMNA 4409/4885ADORA3 958/4885TSHR 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.